Lalit Sharma
1 Papers
Lalit Sharma is an academic researcher. The author has contributed to research in topics: Lung cancer & Erlotinib. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Martin Schuler,Martin Schuler,Jingzhen Yang,Kwan Park,Jeong-Ho Kim,J. Bennouna,Y.-M. Chen,C. Chouaid,F. De Marinis,J.-F. Feng,F. Grossi,D-W. Kim,X. Liu,Shaoyong Lu,J. Strausz,Y. Vinnyk,R. Wiewrodt,C. Zhou,B. Wang,V. K. Chand,D. Planchard,Sai-Hong Ignatius Ou,David Planchard,Keunchil Park,Martin Schuler,James Chih-Hsin Yang,Vikram K. Chand,Klaus Rohr,Claudia Bagnes,Claudio Martin,Gonzalo Recondo,J. J. Zarba,Cesar Blajman,Martín Richardet,Sue-Anne McLachlan,Phillip Parente,Craig Underhill,Catherine Crombie,Paul N. Mainwaring,Richard Greil,Yves Humblet,Frédérique Bustin,Luciano Carestia,Danny Galdermans,Marc Lambrechts,Laetitia Delval,Piet Vercauter,Caicun Zhou,Jin Wang,Cheng Huang,Xiaoyan Lin,Yi-Long Wu,Xiaoqing Liu,Ying Cheng,Shukui Qin,Jifeng Feng,Jianjin Huang,Yiping Zhang,Shun Lu,Manuela Zereu,Bernardo Garicochea,Cyntia Albuquerque Zadra,Henrik Riska,Tuomo Alanko,Jacques Cadranel,Christos Chouaid,Gérard Zalcman,Denis Moro Sibilot,Maurice Perol,Jaafar Bennouna,Pierre Fournel,Radj Gervais,Maciej Rotarski,Bruno Coudert,Michael Thomas,Thomas Wehler,Martin Faehling,Ulrich Keilholz,E. Laack,Joachim von Pawel,Rudolf M. Huber,Nicolas Dickgreber,Rainer Wiewrodt,Zsuzsanna Mark,Sandor Tehenes,Janos Strausz,Veronika Sarosi,Kumar Prabhash,Minish Jain,Srinivasan Venkatesan,Lalit Sharma,Hemant Dadhich,Rajnish Vasant Nagarkar,Amir Onn,Maya Gottfried,Solomon Stemmer,Maria Rita Migliorino,Francesco Grossi,P. Bidoli,Alessandra Bearz,Cesare Gridelli,Carlo Milandri,Marco Platania,Giovanni Luca Ceresoli,Giorgio Cruciani,Francisco Gutierrez Delgado,José Luis Gonzalez Perez,Gabriela Alvarado Luna,Othon Padilla Baca,Joachim G.J.V. Aerts,J.A. Stigt,A-M.C. Dingemans,G.J.M. Herder,S. J. M. Gans,Jorge Fernando Salas Sánchez,Renzo Luzgardo Alvarez Barreda,Wilbert Rodriguez Pantigoso,Osbert Luis Mejia Palomino,Piotr Jaskiewicz,Andrzej Kazarnowicz,Piotr Serwatowski,Aleksandra Szczesna,Jacek Jassem,Vladimir Lubennikov,Nina Karaseva,Sergey Orlov,Yuri Ragulin,Pilar Garrido,José Luis González Larriba,Carlos Camps,Rosario Garcia Campelo,Pilar Lianes,Manuel Cobo,Enriqueta Felip,Dong Wan Kim,Sang-We Kim,Joo Hang Kim,Ji-Youn Han,Young-Chul Kim,Chih-Hsin Yang,Te Chun Hsia,Yuh Min Chen,Ying-Huang Tsai,Gee-Chen Chang,Thomas Chang-Yao Tsao,Wu Chou Su,Ming-Shyan Huang,C. L. Ho,Ruey-Kuen Hsieh,Yuriy Vinnyk,Oleksandr Popovych,Olga Ponomarova,Igor Bondarenko,Iryna Polishchuk,Riyaz Shah,Sanka Mitra,Sanjaykumar Popat,James Spicer,Elizabeth Toy,Toby Talbot,Emma Brown,Sunil Upadhyay,Yvonne Summers,Jayne Gurtler,Luis Meza,John Thropay +165 more
TL;DR: In this prospective phase III trial, afatinib combined with paclitaxel improved progression-free survival and objective response, compared with single-agent chemotherapy, in patients with NSCLC who were clinically enriched for ErbB dependency having failed platinum-based chemotherapy.
129